PCSA - processapharmaceuticals.com Company Long-Term Debts

processapharmaceuticals.com - graphic logo of issuer PCSA

Processa Pharmaceuticals (PCSA) optimizes known molecules to reduce chemotherapy toxicity while establishing a comprehensive biotech hub for drug modification. This chart illustrating the price evolution of the stock demonstrates the asset's dynamics, where long-term debt stands at 0.00. A steady influx of new clinics and FDA support ensure patient retention within the NGC-Cap therapy, closing the treatment loop.

PCSA Processa Pharmaceuticals, Inc. Company Long-Term Liabilities (07/04/2022 - 10/28/2026)

Processa Pharmaceuticals, Inc. - analytical breakdowns and key metrics (PCSA)

- price and consensus price forecast:
Market Price Processa Pharmaceuticals Inc.|PCSA - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Processa Pharmaceuticals|PCSA - Total Company Value
- book capitalization data:
Net Assets per Share Processa Pharmaceuticals|PCSA - Company Net Assets|Market Cap to Book Value Multiple processapharmaceuticals.com|PCSA - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Processa Pharmaceuticals|PCSA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Processa Pharmaceuticals Inc.|PCSA - Company Aggregate Debts|Debts to Book Capitalization Processa Pharmaceuticals|PCSA - Company Long-Term Debt|Company Short-Term Indebtedness Processa Pharmaceuticals
Summary company analytics:Processa Pharmaceuticals (PCSA)
Original product of Processa Pharma

To minimize risks during long-term investing, it is essential to track the total volume of loans with maturities exceeding one year, adjusted for reporting delays. An analysis of Processa Pharmaceuticals (PCSA) long-term borrowings, with a current value of 0.00, allows for an assessment of how financial leverage supports the development of the Regulatory Science platform for modifying the molecular profile of drugs without compromising operating margins or business stability.

Competitor analysis

Long-Term Debt olema.com OLMA|Puma Biotechnology Inc - Company Long-Term Debts|GLSI: Company Long-Term Debts|Zentalis Pharmaceuticals Inc - Company Long-Term Debt|Long-Term Debt Volume MacroGenics Inc.|Plus Therapeutics Inc (PSTV) - Company Long-Term Liabilities|Amount of Long-Term Liabilities Eagle Pharma (EGRX)